Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
NCT05020860
This study is recruiting at 2 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to learn whether clinical response (the amount a tumor shrinks based on imaging or tumor measurements obtained by physical exam) predicts pathologic response (the amount of tumor remaining when surgery is performed) in participants with breast cancer who are receiving chemotherapy prior to surgery.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Breast Cancer
- Breast Neoplasm
- Breast Cancer Female
- Breast Cancer Invasive
- Breast Cancer Stage II
- Breast Cancer Stage III
- Triple Negative Breast Cancer
- Hormone Receptor-positive Breast Cancer
- HER2-positive Breast Cancer
- Triple Negative Breast Neoplasms
- Estrogen Receptor-positive Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Baylor Breast Care Center
- Last updated on ClinicalTrials.gov
- February 27, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Texas · 2
- Harris Health System - Smith Clinic · Houston, TX
- O'Quinn Medical Tower - McNair Campus - Dan L Duncan Comprehensive Cancer Center · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.